Edward Tenthoff

Stephen Willey

David Bautz

Swayampakula Ramakanth

Kristen Kluska

Ayan Hussein

Douglas Macpherson

Leah Rush Cann

- **X4 Pharmaceuticals announced a strategic restructuring** on September 17, 2025, which includes a **50% reduction in its workforce**.  **[1501697_0001501697-25-000021_ex991_2025916release.htm:0]** **[1501697_0001501697-25-000021_xfor-20250915.htm:1]** 
- This initiative is anticipated to generate **annualized cost savings of approximately $13 million**.  **[1501697_0001501697-25-000021_ex991_2025916release.htm:0]** **[1501697_0001501697-25-000021_xfor-20250915.htm:1]** 
- The company estimates it will incur **cash charges of approximately $3.3 million** for severance and other employee termination-related costs, with the workforce reduction substantially completed in the third quarter of 2025.  **[1501697_0001501697-25-000021_xfor-20250915.htm:1]** 
- As part of the restructuring, **John Volpone was appointed Chief Operating Officer** in addition to his role as President, while the **former Chief Operating Officer, Chief Commercial Officer, Chief Legal & Compliance Officer, and Chief Medical Officer are exiting** the company.  **[1501697_0001501697-25-000021_ex991_2025916release.htm:0]** **[1501697_0001501697-25-000021_xfor-20250915.htm:2]**

X4 Pharmaceuticals (XFOR)